X Grimaux1, S Leducq1, P Goupille2, A Aubourg3, E Miquelestorena-Standley4, M Samimi5. 1. Université François-Rabelais, 37000 Tours, France; Service de dermatologie, CHU, hôpital Trousseau, 37044 Tours cedex, France. 2. Université François-Rabelais, 37000 Tours, France; Service de rhumatologie, CHU, hôpital Trousseau, 37044 Tours cedex, France. 3. Université François-Rabelais, 37000 Tours, France; Service d'hépato-gastro-onco-entérologie, CHU, hôpital Trousseau, 37044 Tours cedex, France. 4. Université François-Rabelais, 37000 Tours, France; Service d'anatomie et cytologie pathologiques, CHU, hôpital Trousseau, 37044 Tours cedex, France. 5. Université François-Rabelais, 37000 Tours, France; Service de dermatologie, CHU, hôpital Trousseau, 37044 Tours cedex, France; Équipe BIP, ISP 1282 INRA-Université de Tours, 37000 Tours, France. Electronic address: mahtab.samimi@univ-tours.fr.
Abstract
BACKGROUND: Secukinumab, a humanized monoclonal antibody targeting interleukin 17A, has been associated with the development of inflammatory bowel diseases. We report a case of a female patient developing recurrent oral ulcers prior to inflammatory bowel disease induced by secukinumab. The patient had developed similar oral ulcers 6 years earlier while on tocilizumab (targeting IL6R), suggesting an immunological link between the two episodes. PATIENTS AND METHODS: A 36-year-old female patient had refractory spondylarthrosis. In 2010, she had presented oral aphthous ulcers during treatment with tocilizumab. In 2011, tocilizumab was stopped and the ulcers resolved. In 2016, secukinumab was introduced and led to recurrence of oral aphthous ulcers followed by ileitis-pancolitis. Corticosteroids and ustekinumab resulted in partial remission. DISCUSSION: The patient developed inflammatory bowel disease during treatment with secukinumab, preceded by recurrent oral aphthous ulcers. She had presented similar oral ulcers 6 years earlier while on a treatment targeting IL6R. IL6 is a pleiotropic cytokine that may activate the Th17 pathway. Thus, tocilizumab could have induced an "anti-IL17-like" effect, accounting for the occurrence of oral aphthous ulcers, possibly related to mild inflammatory bowel disease. CONCLUSION: The occurrence of oral ulcers during treatment with secukinumab may herald inflammatory bowel disease. In patients with a previous history of recurrent aphthous stomatitis, especially where induced by previous biologics, consideration must be given to the risk-benefit ratio of prescribing an anti-IL17 antibody.
BACKGROUND:Secukinumab, a humanized monoclonal antibody targeting interleukin 17A, has been associated with the development of inflammatory bowel diseases. We report a case of a female patient developing recurrent oral ulcers prior to inflammatory bowel disease induced by secukinumab. The patient had developed similar oral ulcers 6 years earlier while on tocilizumab (targeting IL6R), suggesting an immunological link between the two episodes. PATIENTS AND METHODS: A 36-year-old female patient had refractory spondylarthrosis. In 2010, she had presented oral aphthous ulcers during treatment with tocilizumab. In 2011, tocilizumab was stopped and the ulcers resolved. In 2016, secukinumab was introduced and led to recurrence of oral aphthous ulcers followed by ileitis-pancolitis. Corticosteroids and ustekinumab resulted in partial remission. DISCUSSION: The patient developed inflammatory bowel disease during treatment with secukinumab, preceded by recurrent oral aphthous ulcers. She had presented similar oral ulcers 6 years earlier while on a treatment targeting IL6R. IL6 is a pleiotropic cytokine that may activate the Th17 pathway. Thus, tocilizumab could have induced an "anti-IL17-like" effect, accounting for the occurrence of oral aphthous ulcers, possibly related to mild inflammatory bowel disease. CONCLUSION: The occurrence of oral ulcers during treatment with secukinumab may herald inflammatory bowel disease. In patients with a previous history of recurrent aphthous stomatitis, especially where induced by previous biologics, consideration must be given to the risk-benefit ratio of prescribing an anti-IL17 antibody.